The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model

Posaconazole is more active than fluconazole against Candida albicans in vitro and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic/pharmacodynam...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrob Agents Chemother
Main Authors: Beredaki, Maria-Ioanna, Arendrup, Maiken Cavling, Andes, David, Mouton, Johan W., Meletiadis, Joseph
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2021
Subjects:
Susceptibility
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8097413/
https://ncbi.nlm.nih.gov/pubmed/33468486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01292-20
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items